DARWIN EU data partners onboarded in phases I, II and III
Submitted by Anonymous (not verified) on 20 February 2025 - 22:10
DARWIN EU data partners onboarded in phases I, II and III
Human medicines European public assessment report (EPAR): Victoza, liraglutide, Date of authorisation: 30/06/2009, Revision: 25, Status: Authorised
Submitted by Anonymous (not verified) on 20 February 2025 - 15:05
Human medicines European public assessment report (EPAR): Victoza, liraglutide, Date of authorisation: 30/06/2009, Revision: 25, Status: Authorised
How to recognise scams using EMA credentials
Submitted by Anonymous (not verified) on 20 February 2025 - 14:54
How to recognise scams using EMA credentials
Minutes of the CVMP meeting 14-15 January 2025
Submitted by Anonymous (not verified) on 20 February 2025 - 14:30
Minutes of the CVMP meeting 14-15 January 2025
Orphan designation: Rilzabrutinib Treatment of autoimmune haemolytic anaemia, 16/01/2025 Positive
Submitted by Anonymous (not verified) on 20 February 2025 - 14:22
Orphan designation: Rilzabrutinib Treatment of autoimmune haemolytic anaemia, 16/01/2025 Positive
Orphan designation: Clofutriben Treatment of Cushing's syndrome of endogenous origin, 16/01/2025 Positive
Submitted by Anonymous (not verified) on 20 February 2025 - 14:16
Orphan designation: Clofutriben Treatment of Cushing's syndrome of endogenous origin, 16/01/2025 Positive
Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn
Submitted by Anonymous (not verified) on 20 February 2025 - 14:10
Orphan designation: xevinapant Treatment of ovarian cancer, 11/11/2015 Withdrawn
Orphan designation: Adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor Treatment of hereditary angioedema, 10/11/2022 Withdrawn
Submitted by Anonymous (not verified) on 20 February 2025 - 14:10
Orphan designation: Adeno-associated virus serotype 5 vector encoding C1-esterase inhibitor Treatment of hereditary angioedema, 10/11/2022 Withdrawn
Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel) Treatment of Wiskott-Aldrich syndrome, 07/10/2013 Withdrawn
Submitted by Anonymous (not verified) on 20 February 2025 - 14:09
Orphan designation: Autologous CD34+ cells transfected with lentiviral vector containing the Wiskott-Aldrich syndrome protein gene (etuvetidigene autotemcel) Treatment of Wiskott-Aldrich syndrome, 07/10/2013 Withdrawn
Orphan designation: amitriptyline Treatment of erythromelalgia, 21/06/2022 Withdrawn
Submitted by Anonymous (not verified) on 20 February 2025 - 14:08
Orphan designation: amitriptyline Treatment of erythromelalgia, 21/06/2022 Withdrawn